UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Recent Advances in the Treatment of Malignant Astrocytoma

Journal of clinical oncology, 2006-03, Vol.24 (8), p.1253-1265

2006

Volltextzugriff (PDF)

Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma

Journal of clinical oncology, 2003-02, Vol.21 (4), p.646-651

2003

Volltextzugriff (PDF)

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas

Journal of clinical oncology, 2002-03, Vol.20 (5), p.1389

2002

Volltextzugriff (PDF)

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma

Journal of clinical oncology, 2002-05, Vol.20 (9), p.2277

2002

Volltextzugriff (PDF)

Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas

Journal of clinical oncology, 2000-11, Vol.18 (22), p.3862-3872

2000

Volltextzugriff (PDF)

Phase II Trial of Temozolomide Plus O 6 -Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma

Journal of clinical oncology, 2009-03, Vol.27 (8), p.1262-1267

2009

Volltextzugriff (PDF)

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e14015-e14015

2022

Volltextzugriff (PDF)

A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors

Journal of clinical oncology, 2017-03, Vol.35 (7_suppl), p.102-102

2017

Volltextzugriff (PDF)

Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4

Journal of clinical oncology, 2017-03, Vol.35 (7_suppl), p.74-74

2017

Volltextzugriff (PDF)

Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.2566-2566

2020

Volltextzugriff (PDF)

Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e12641-e12641

2018

Volltextzugriff (PDF)

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2060-2060

2019

Volltextzugriff (PDF)

Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e13532-e13532

2017

Volltextzugriff (PDF)

Phase I Trial of Temozolomide Plus O 6 -Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma

Journal of clinical oncology, 2005-10, Vol.23 (28), p.7178-7187

2005

Volltextzugriff (PDF)

Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.2061-2061

2016

Volltextzugriff (PDF)

Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e13518-e13518

2016

Volltextzugriff (PDF)

Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e13533-e13533

2017

Volltextzugriff (PDF)

Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM)

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e13030-e13030

2015

Volltextzugriff (PDF)

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.2068-2068

2015

Volltextzugriff (PDF)

Reply to M.C. Chamberlain

Journal of clinical oncology, 2011-06, Vol.29 (17), p.e519-e520

2011

Volltextzugriff (PDF)

Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.2094-2094

2013

Volltextzugriff (PDF)

Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3069-3069

2014

Volltextzugriff (PDF)

Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS2106-TPS2106

2014

Volltextzugriff (PDF)

Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma

Journal of clinical oncology, 1999-05, Vol.17 (5), p.1516-1525

1999

Volltextzugriff (PDF)

Reply to M.S. Lesniak

Journal of clinical oncology, 2011-08, Vol.29 (22), p.3105-3106

2011

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Aktive Filter

KollektionAmerican Association for the Advancement of Science

ThemaTumors Of The Nervous System. Phacomatoses

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Oncology
(11)
Science & Technology
(11)
Humans
(10)
Adult
(9)
Middle Aged
(9)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Female
(7)
Male
(7)
Antineoplastic Agents
(5)
Chemotherapy
(5)
Combined Modality Therapy
(5)
Pharmacology. Drug Treatments
(5)
Aged
(4)
Glioma - Drug Therapy
(4)
Treatment Outcome
(4)
Antibodies, Monoclonal - Adverse Effects
(3)
Brain Neoplasms - Drug Therapy
(3)
Dacarbazine - Analogs & Derivatives
(3)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Recent Advances in the Treatment of Malignant Astrocytoma

Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas

Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma

Phase I Trial Results of Iodine-131–Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas

Phase II Trial of Temozolomide Plus O 6 -Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG)

A combinatorial immunotherapy for malignant brain tumors: D2C7 immunotoxin and immune checkpoint inhibitors

Immunotoxin and bcl-2 inhibitor combination therapy targeting chondroitin sulfate proteoglycan 4

Phase I trial of D2C7 immunotoxin (D2C7-IT) administered intratumorally via convection-enhanced delivery (CED) for recurrent malignant glioma (MG)

Recombinant oncolytic poliovirus combined with checkpoint blockade for breast cancer therapy

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG): Experience with retreatment of survivors from the phase I trial

Phase 1 single-center, dose escalation study of D2C7-IT administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma

Phase I Trial of Temozolomide Plus O 6 -Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma

Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls

Phase I trial of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly-diagnosed glioblastoma multiforme (GBM)

Dose finding study of the intratumoral administration of the oncolytic polio/rhinovirus recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG)

Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM)

Oncolytic polio/rhinovirus recombinant (PVSRIPO) against recurrent glioblastoma (GBM): Optimal dose determination

Reply to M.C. Chamberlain

Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma

Regulatory T-cell inhibition plus antitumor immunotherapy targeted against cytomegalovirus (CMV) in patients with newly diagnosed glioblastoma multiforme (GBM)

Phase I study of the intratumoral administration of an oncolytic polio/rhinovirus recombinant (PVSRIPO) in recurrent glioblastoma (GBM)

Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma

Reply to M.S. Lesniak

Aktive Filter

Suchergebnisse filtern